• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Halaven (Eribulin Mesylate) Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 


August 2014

Summary View


Postmarketing Experience
  • Blood and Lymphatic System Disorders: lymphopenia …
  • Hepatobiliary Disorders: hepatotoxicity
  • Immune System Disorders: drug hypersensitivity
  • Infections and Infestations: pneumonia, sepsis/neutropenic sepsis
  • Metabolism and Nutrition Disorders: hypomagnesemia, dehydration
  • Respiratory, thoracic and mediastinal disorders: interstitial lung disease
  • Skin and Subcutaneous Tissue Disorders: pruritus


August 2013

Summary View 


Postmarketing Experience
  • The following adverse drug reaction has been identified during post-approval of HALAVEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal Disorders: Pancreatitis